Literature DB >> 27943680

Progression of Lung Disease in Preschool Patients with Cystic Fibrosis.

Sanja Stanojevic1,2, Stephanie D Davis3, George Retsch-Bogart4, Hailey Webster2, Miriam Davis3, Robin C Johnson4, Renee Jensen2, Maria Ester Pizarro2,5, Mica Kane2, Charles C Clem3, Leah Schornick3, Padmaja Subbarao1,2, Felix A Ratjen1,2.   

Abstract

RATIONALE: Implementation of intervention strategies to prevent lung damage in early cystic fibrosis (CF) requires objective outcome measures that capture and track lung disease.
OBJECTIVES: To define the utility of the Lung Clearance Index (LCI), measured by multiple breath washout, as a means to track disease progression in preschool children with CF.
METHODS: Children with CF between the ages of 2.5 and 6 years with a confirmed diagnosis of CF and age-matched healthy control subjects were enrolled at three North American CF centers. Multiple breath washout tests were performed at baseline, 1, 3, 6, and 12 months to mimic time points chosen in clinical care and interventional trials; spirometry was also conducted. A generalized linear mixed-effects model was used to distinguish LCI changes associated with normal growth and development (i.e., healthy children) from the progression of CF lung disease.
MEASUREMENTS AND MAIN RESULTS: Data were collected on 156 participants with 800 LCI measurements. Although both LCI and spirometry discriminated health from disease, only the LCI identified significant deterioration of lung function in CF over time. The LCI worsened during cough episodes and pulmonary exacerbations, whereas similar symptoms in healthy children were not associated with increased LCI values.
CONCLUSIONS: LCI is a useful marker to track early disease progression and may serve as a tool to guide therapies in young patients with CF.

Entities:  

Keywords:  cystic fibrosis; disease progression; lung clearance index; lung function

Mesh:

Year:  2017        PMID: 27943680      PMCID: PMC5439018          DOI: 10.1164/rccm.201610-2158OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  25 in total

Review 1.  An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.

Authors:  Nicole Beydon; Stephanie D Davis; Enrico Lombardi; Julian L Allen; Hubertus G M Arets; Paul Aurora; Hans Bisgaard; G Michael Davis; Francine M Ducharme; Howard Eigen; Monika Gappa; Claude Gaultier; Per M Gustafsson; Graham L Hall; Zoltán Hantos; Michael J R Healy; Marcus H Jones; Bent Klug; Karin C Lødrup Carlsen; Sheila A McKenzie; Francçois Marchal; Oscar H Mayer; Peter J F M Merkus; Mohy G Morris; Ellie Oostveen; J Jane Pillow; Paul C Seddon; Michael Silverman; Peter D Sly; Janet Stocks; Robert S Tepper; Daphna Vilozni; Nicola M Wilson
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

2.  Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.

Authors:  Sanja Stanojevic; Alexandra McDonald; Valerie Waters; Sarah MacDonald; Eric Horton; Elizabeth Tullis; Felix Ratjen
Journal:  Thorax       Date:  2016-08-18       Impact factor: 9.139

3.  Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis.

Authors:  Richard Kraemer; Andrea Blum; Andreas Schibler; Roland A Ammann; Sabina Gallati
Journal:  Am J Respir Crit Care Med       Date:  2004-11-05       Impact factor: 21.405

4.  Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis.

Authors:  Paul Aurora; Andrew Bush; Per Gustafsson; Cara Oliver; Colin Wallis; John Price; John Stroobant; Siobhan Carr; Janet Stocks
Journal:  Am J Respir Crit Care Med       Date:  2004-10-29       Impact factor: 21.405

5.  Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection.

Authors:  Shannon J Simpson; Sarath Ranganathan; Judy Park; Lidija Turkovic; Roy M Robins-Browne; Billy Skoric; Kathryn A Ramsey; Tim Rosenow; Georgia L Banton; Luke Berry; Stephen M Stick; Graham L Hall
Journal:  Eur Respir J       Date:  2015-09-17       Impact factor: 16.671

6.  Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Mark O Wielpütz; Simon Y Graeber; Cornelia Joachim; Olaf Sommerburg; Hans-Ulrich Kauczor; Michael Puderbach; Monika Eichinger; Marcus A Mall
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

7.  Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.

Authors:  Jane Davies; Helen Sheridan; Nicholas Bell; Steve Cunningham; Stephanie D Davis; J Stuart Elborn; Carlos E Milla; Timothy D Starner; Daniel J Weiner; Po-Shun Lee; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2013-09-10       Impact factor: 30.700

8.  Lung function in infants with cystic fibrosis diagnosed by newborn screening.

Authors:  Barry M Linnane; Graham L Hall; Gary Nolan; Siobhan Brennan; Stephen M Stick; Peter D Sly; Colin F Robertson; Philip J Robinson; Peter J Franklin; Stephen W Turner; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

10.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

View more
  24 in total

1.  Comparison of Multiple Breath Washout and Spirometry in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis and Healthy Controls.

Authors:  BreAnna Kinghorn; Sharon McNamara; Alan Genatossio; Erin Sullivan; Molly Siegel; Irma Bauer; Charles Clem; Robin C Johnson; Miriam Davis; Anne Griffiths; William Wheeler; Katherine Johnson; Stephanie D Davis; Margaret W Leigh; Margaret Rosenfeld; Jessica Pittman
Journal:  Ann Am Thorac Soc       Date:  2020-09

2.  Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations.

Authors:  Hartmut Grasemann; Pierluigi Ciet; Reshma Amin; Nancy McDonald; Michelle Klingel; Harm A W M Tiddens; Felix Ratjen; Lars Grosse-Wortmann
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

3.  Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

Authors:  Felix Ratjen; Michelle Klingel; Philip Black; Michael R Powers; Hartmut Grasemann; Melinda Solomon; Scott D Sagel; Scott H Donaldson; Steven M Rowe; Margaret Rosenfeld
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

4.  Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

Authors:  Jennifer Guimbellot; George M Solomon; Arthur Baines; Sonya L Heltshe; Jill VanDalfsen; Elizabeth Joseloff; Scott D Sagel; Steven M Rowe
Journal:  J Cyst Fibros       Date:  2018-04-21       Impact factor: 5.482

5.  Defining and identifying early-onset lung disease in cystic fibrosis with cumulative clinical characteristics.

Authors:  Leslie Huang; HuiChuan J Lai; Nicholas Antos; Michael J Rock; Fadi Asfour; Michelle Howenstine; Jonathan M Gaffin; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2022-06-25

Review 6.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

7.  Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.

Authors:  Jordana E Hoppe; Brandie D Wagner; Scott D Sagel; Frank J Accurso; Edith T Zemanick
Journal:  BMC Pulm Med       Date:  2017-12-11       Impact factor: 3.317

Review 8.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

9.  Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.

Authors:  Michelle Shaw; Umer Khan; John P Clancy; Scott H Donaldson; Scott D Sagel; Steven M Rowe; Felix Ratjen
Journal:  J Cyst Fibros       Date:  2020-06-06       Impact factor: 5.527

10.  Inter-test reproducibility of the lung clearance index measured by multiple breath washout.

Authors:  Esther Oude Engberink; Felix Ratjen; Stephanie D Davis; George Retsch-Bogart; Reshma Amin; Sanja Stanojevic
Journal:  Eur Respir J       Date:  2017-10-05       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.